Lupus
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment)
- 71% had LN (No class IV or Mixed)
- 46% actionable LN
Cost-effectiveness data needed.
#ACRBest @RheumNow https://t.co/Bt3fuA3aJh
Dr M Nazibur Rahman, MD (Rheumatology) NaziburM
3 months ago
Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe
The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.
Mrinalini Dey DrMiniDey
3 months ago
Plenary session at #ACR25!
#0772 When should we biopsy in SLE?
In pts with uPCR 0.25-0.49 g/g + LN predictors, 69% already had LN (many Class III/V). Low C3/C4 were most important factors.
0.5 g/g cutoff may delay diagnosis and treatment. Time to rethink thresholds? @RheumNow
Brian Jaros, MD Dr_Brian_MD
3 months ago
Early, low level proteinuria is a harbinger in SLE. ~50% with elevated UPCR but <0.5 had actionable LN on early bx.
Risk factor = low c3/c4
Urine biomarkers promising
#ACRBest #ACR25 @RheumNow https://t.co/WuNPKeqeid
Brian Jaros, MD Dr_Brian_MD
3 months ago
From Dr. Petri at Plenary - even small amounts of proteinuria are a PROBLEM. Reduction of microalbuminuria by even 10% improves mortality! #ACR25 @RheumNow https://t.co/hjmH26vXIb
David Liew drdavidliew
3 months ago
Topical therapies in cutaneous lupus - find the right level
Victoria Werth #ACR25 SLE guideline session @RheumNow https://t.co/o3gBuFkr4n
sheila RHEUMarampa
3 months ago
For #SLE pleuropericarditis: recommendation intentionally tries to leverage use of colchicine/NSAIDs vs. GCs
But there are special situations where GCs are req’d:
> Concomitant active SLE
> CI to NSAIDs/Col
> Recurrent pericarditis
> Late pregnancy
> 💊interxns
#ACR25 @RheumNow https://t.co/sLL72t3Qhf
Gabriela Martinez Zayas, MD MartinezZayasMd
3 months ago
HIGH YIELD🚨Summary of Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ysSTKOz1ym
sheila RHEUMarampa
3 months ago
Year in Review: Regency Trial showed that LN pts given obinutuzumab achieved CRR at 76 wks (46.4%) vs. PBO.
Take note: the Regency trial did not evaluate the extrarenal effects of Obinutuzumab in #SLE, thats for a diff study.
#ACR25 @RheumNow https://t.co/WJssU1DbzZ
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 New ACR Non-Renal #SLE lifecourse Guideline. 3 strong recommendations:
- HCQ routinely unless contraindicated
- Taper GC to =< 5mg/d
- Escalate therapy in any organ system if refractory to initial therapy
*Organ-specific: Conditional recommendations only
@RheumNow https://t.co/w9rfcvwGHy
At ACR Convergence 2025, the American College of Rheumatology presents new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, antiphospholipid syndrome, and lupus.
David Liew drdavidliew
3 months ago
@ACRheum SLE Treatment Guidelines 2025
Key points:
- HCQ is standard
- steroids with precision
- immunosuppressive therapies early
- shared decision making
#ACR25 @RheumNow https://t.co/AYIXE6dLlW
Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and long-term disease remission.
Dr. John Cush RheumNow
3 months ago
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen.
Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z
Poster Hall